The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

While immunotherapies like Keytruda have transformed the treatment of certain cancers ... PESG Research is a digital commentary brand, offering coverage and exploration into companies and sectors in ...

Immutep (ASX:IMM) has reported that eftilagimod alpha (efti) combined with MSD's KEYTRUDA® shows high efficacy and a favourable safety profile for treating head and neck cancer. The TACTI-003 trial ...